GSK at a glance
At GSK, we prevent and treat disease with specialty medicines, vaccines and general medicines.
We're a focused biopharma company with strong momentum and big ambitions. We're pursuing research and development across four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
A focused biopharma company
- 66,800
People worldwide
- 70
Countries we operate in
- 33
Manufacturing sites
- £7.5bn
R&D investment in 2025
- 5
FDA approvals in 2025
- 14
New partnerships and acquisitions in 2025
- 7
Positive phase III data read-outs in 2025
- >2bn
Packs of medicines and vaccine doses supplied
- £32.7bn
Group turnover in 2025
- 7%
Sales growth in 2025
- £8bn
Innovation sales in 2025
- 92%
Of our Responsible Business Performance Rating metrics ‘met’ or ‘exceeded’ in 2025
- 2nd
In the Access to Medicine Index
- 14%
Reduction in operational carbon emissions since 2024 (scope 1 and 2)
- 1st
To pioneer HIV treatments in 1980 and leaders in HIV innovation
- 4/5
Product approvals in 2025 in specialty medicines
- >30%
Of sales generated by specialty medicines
